Levetiracetam for prophylactic treatment of pediatric migraine: A randomized double-blind placebo-controlled trial by Montazerlotfelahi, H et al.
Levetiracetam for Prophylactic Treatment of Pediatric Migraine: A Randomized Double-
Blind Placebo-Controlled trial 
 
 
Hadi Montazerlotfelahi1,*, Man Amanat2,*,Ali Reza Tavasoli3, Elmira Agah2,4, Gholam Reza 
Zamani3, Josemir W. Sander5-7, Reza Shervin Badv3, Mahmoud Mohammadi3, Mahdieh 
Dehghani8, Morteza Heidari3, Seyed Ahmad Hosseini9,Mahmoud Reza Ashraﬁ3,**  
 
1) Pediatrics Center of Excellence, Department of Pediatric Neurology, Alborz University of Medical 
Sciences, Karaj, Iran 
 
2) Faculty of Medicine, Students’ Scientific Research Center, Tehran University of Medical Sciences, 
Tehran, Iran 
 
3)  Pediatrics Center of Excellence, Department of Pediatric Neurology, Children’s Medical Center,  
Growth and Development Research Center , Tehran University of Medical Sciences, Tehran, Iran 
 
4) NeuroImmunology Research Association (NIRA), Universal Scientific Education and Research 
Network  (USERN), Tehran, Iran. 
 
5) Stichting Epilepsie Instellingen Nederland (SEIN), Achterweg 5, Heemstede 2103SW, Netherlands 
 
6) NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square 
Institute of Neurology, London WC1N 3BG, and Chalfont Centre for Epilepsy, Chalfont St Peter, 
Bucks, SL9 0RJ, United Kingdom  
 
 
7) Faculty of Medicine, Yazd University of Medical Sciences,Yazd, Iran  
 
8) Department of Pediatric Neurology, Golestan University of Medical Sciences, Golestan, Iran 
 
 
 
*Hadi Montazerlotfelahi and Man Amanat contributed equally to this work. 
 
**Corresponding Author: Mahmoud Reza Ashrafi. Pediatrics Center of Excellence, 
Department of Pediatric Neurology, Children’s Medical Center, Growth and Development 
Research Center, Tehran University of Medical Sciences, Tehran, Iran 
E-mail: ashrafim@tums.ac.ir , Tel/fax: +98 21 66935848  
 
 
 
 
 
 
             
 
 
 
  
 Abstract 
 
Introduction: Few drugs are available for migraine prophylaxis in children. 
Levetiracetam is a broad spectrum anti-seizure drug which has been suggested to be  
effective in reducing adult migraine episodes. We assessed the safety and efficacy of 
levetiracetam in the prevention of pediatric migraine. Methods: A randomized double-
blind placebo-controlled trial was performed. Eligible participants were aged 4-17 years 
old with at least four migraineous episodes monthly or had severe disabling or 
intolerable episodes. Primary endpoints were the mean changes in monthly frequency 
and intensity of headaches from the baseline phase to the last month of the double-
blind phase. Safety endpoint was the adverse effects reported . Results: Sixty one 
participants (31 taking levetiracetam and 30 taking placebo) completed the study. All 
had a significant reduction in frequency and intensity of episodes which was significantly 
greater in the levetiracetam arm. Sixty eight percent of individuals in the treatment 
group reported more than 50% reduction of episodes at the end of the trial compared 
with 30% in placebo group (P-value: 0.0074). Irritability, day-time sedation, and mild tic 
were reported. Conclusion: Levetiracetam may be useful in migraine prevention and 
may decrease migraine episodes and severity. 
 
  Trial Registration: The study is prospectively registered with Iranian Registry of Clinical 
Trials; IRCT.ir, number IRCT2017021632603N1. 
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Introduction 
 
 Up to 8% of children and adolescents may have migraine (1). About half of children and 
adolescents with migraine will continue to experience episodes into adulthood (2,3), 
leading to disability with substantial social and financial burdens to the individual as well 
as society. 
 
Migraine prophylaxis may reduce the burden of the condition (4).  To prevent analgesic 
overuse and to help children have normal daily activity, migraine preventive medications 
should be used when the number of headache episodes exceeds four per month or 
when quality of life, school attendance or daily activities are restricted (5,6). Few high 
quality studies to identify medications with reasonable prophylactic effect have been 
conducted in pediatric migraine. Topiramate is the only prophylactic agent of migraine in 
children older than 12 years approved by the Food and Drug Administration (FDA). A 
recent phase 3, multicenter, double-blind, placebo-controlled trial, however, suggested 
that topiramate was not different from placebo in reducing events in children and 
adolescents (7). Further work is needed to identify the best evidence-based 
pharmaceutical interventions.  
 
Anti-seizure medications (ASMs) are commonly used in migraine prevention. 
Randomized controlled trials evaluated the efficacy of 15 ASMs as migraine prophylaxis 
in adults (8). Topiramate, valproic acid, levetiracetam, zonisamide and gabapentin have 
also been used in a few studies to prevent childhood and adolescent migraine (9). Our 
aim was to assess the safety and efficacy of levetiracetam in prevention of pediatric 
migraine. 
 
Methods 
 
Study design and participants 
 
A randomized, double-blind placebo-controlled trial in the Children’s Medical Center, a 
major referral hospital affiliated to Tehran University of Medical Sciences was 
performed.  The trial was divided into three phases: 1) initial screening phase (2 weeks), 
a baseline phase (4 weeks), and a double-blind treatment phase (12 weeks). Other 
preventive pharmacologic treatment was not allowed during the trial or in the 2 months 
prior to baseline (Appendix, p. 1). Use of abortive migraine medications including simple 
analgesics (e.g., acetaminophen, ibuprofen, ketorolac), triptan-based (e.g., sumatriptan, 
zolmitriptan), and ergot-derivative-based (e.g., ergotamine, dihydroergotamine) 
migraine medications were permitted but participants should not change the rescue 
drugs during the study period. 
 
Children aged 4-17 years who met the diagnostic criteria for pediatric migraine (with or 
without aura) as defined by the International Headache Society (10) were enrolled. They 
had to have at least four migraineous episodes per month or to have severe disabling or 
intolerable headache. They were excluded if they had any of the following: 
 
- History of cluster headache, hemiplegic migraine, or chronic daily headaches 
- Headaches related to structural brain lesions 
- Focal neurologic deficit 
- No therapeutic response to at least three adequate trials of medication for 
headache prophylaxis  
- History of levetiracetam sensitivity 
- Pregnancy 
- Other neurological conditions (e.g. epilepsy)  
 
The ethics committee of Tehran University of Medical Sciences approved the final 
protocol (Number: IR.TUMS.VCR.REC.1395-811). The method was explained to all 
involved. Parents provided written informed consent before initiation of any study 
procedures. The study is prospectively registered with Iranian Registry of Clinical Trials; 
IRCT.ir, number IRCT2017021632603N1. 
 
Randomization and blinding  
 
Eligible participants were randomly assigned to receive either levetiracetam or placebo 
in a 1:1 ratio by permuted block randomization (block sizes of four) via an interactive 
web response system. The responsible statistician was not involved in study conduct or 
monitoring. Some hospital personnel involved in the preparation of the trial material 
were not blinded but had no contact with participants, their parents, or investigators. 
The study medications were coded and administered by a nurse who was not informed 
about the clinical characteristics of cases. The study personnel, investigators, 
participants, and their parents were blinded during the course of the study until the code 
was broken at trial end. Packaging, size (18mm x 8mm), shape  (oval), and color 
(yellow) of placebo tablets were similar to the 500 mg levetiracetam tablets used.  
 
Procedures 
 
Phase 1& 2 
 
All children had complete physical examinations. Neuro-imaging was performed if 
clinically indicated. Laboratory screening tests including blood count (hemoglobin, white 
blood cells, and platelets), serum chemistry. Urine pregnancy testing were performed if 
appropriate (phase 1). Headache diaries were provided for each child, and the parent 
who had more contact with the child was responsible for recording events in the diary. A 
simple form of migraine diagnostic criteria (including criteria B-D) (10) translated into the 
Farsi  language was also provided and explained to the responsible parent so that only 
migraineous episodes were reported. To avoid information bias, parents were asked to 
collect the data in real time, every day and not retrospectively. The number of migraine 
episodes and the intensity of the attacks were recorded using a questionnaire for a 
period of 4 weeks (phase 2) before initiation of double-blind phase. 
 
Phase 3 
   
In the 12-week double-blind phase, oral levetiracetam was administered to the 
treatment group. The initial dose was usually about 20 mg/kg/day divided into two doses 
but varied at the discretion of the study team (up to 40 mg/kg/day). Parents recorded 
migraine frequency and intensity daily. The first follow-up visit was one week after the 
initiation of treatment to check whether the medication had been taken at the correct 
times and doses and whether any adverse effects had occurred. Subsequent follow-up 
visits were at 4, 8, and 12 weeks. Participation was discontinued if 1) any adverse event 
occurred that, in the opinion of the investigator, required termination of medication; 2) 
there was progression of migraine attacks; 3) the participant became pregnant; or 4) 
consent was withdrawn. 
 
Outcomes 
 
The primary endpoints were the mean changes in monthly attack frequency and 
severity of migraine headaches from the baseline phase to the last four weeks of 
treatment. Migraine frequency was defined as the number of attacks that fulfilled the 
IHS criteria for migraine with or without aura (10). In each arm, we obtained the mean 
number of these episodes every four weeks after initiation of treatment. 
 
Migraine intensity was reported using a visual analogue scale (VAS). This scale 
consists of a 10cm line divided into 10 parts, numbered 0 (no pain) to 10 (most extreme 
pain). In each group, we obtained the mean of migraine intensity every four weeks after 
initiation of treatment. 
 
The secondary endpoint was the >50% responder rate. The drug was defined as 
effective if it decreased headache frequency by more than 50% in the double-blind 
phase compared with the baseline frequency. 
 
For the safety endpoint all participants and their parents were asked to report any side 
effects of the medications during their monthly visits. A phone number was also 
provided so adverse events could be reported. Participants and their parents were 
asked to go to the emergency department if serious complications occurred.  
 
Statistical analysis 
 
Based on previous placebo-controlled trials in migraine, we assumed a 40% reduction 
in migraine attack frequency with standard deviation (SD) 50% for sample size 
calculation. Power analysis mandated at least 25 cases per group (11) with α (the 
probability of type I error) as 0.05, and β (the probability of type II error (1 − power of the 
test)) as 0.20. Considering a 20% dropout rate, a final sample size of 30 subjects in 
each treatment arm was estimated. The formula used for sample size calculation was: 
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σ: Variance of mean;  Δ: Absolute difference between two means;  z: Critical value for a given α or β 
 
 
Statistical analysis was performed by the statistician who was masked to the study 
arms. Continuous variables were reported as mean with SD, standard error mean 
(SEM), or 95% confidence interval (CI). Categorical variables were reported using 
percentages. Analyses of between-group differences were performed using intention to 
treat (ITT) approach. All individuals randomized who received at least one dose of the 
study drug were included. Missing data was handled by multiple imputation. Secondary 
analyses were also performed for participants who completed the trial.  
The mean change in frequency and intensity of migraine attacks during weeks 9-12 
were compared between the two treatment arms using t-test for two independent 
samples. To more rigorously evaluate the robustness of the treatment effect, analysis of 
covariance (ANCOVA) models with adjustment for covariates including age, gender, 
and baseline migraine frequency or intensity was performed as a supplemental 
analysis. Fisher’s exact test was used for the secondary endpoint (>50% responder 
rate) analysis. Participants who failed to complete the study were considered non-
responders. IBM SPSS Statistics version 25 was used for statistical analyses. Figures 
were made using GraphPad Prism version 7.04. 
 
Results 
 
  Participants 
The initial phase started in July 2017. Double-blind treatment was given from August 
2017 when the first participant was assigned to August 2018. Eighty-six individuals were 
screened for eligibility, of whom 68 were eligible and were randomly assigned to a 
treatment group (34 in each group). Each took at least one dose of the allocated drug 
and was therefore eligible for the ITT analysis. Of these 68 included subjects, three 
receiving levetiracetam and four receiving placebo did not complete the study. Reasons 
for drop-out were: lost to follow-up (n=3), poor compliance (n=3), and withdrew consent 
without providing any specific reason (n=1). No adverse event was reported by these 
participants. Overall 61 individuals (31 on levetiracetam) completed the study (Figure 1). 
The baseline characteristics of the participants are summarized in Table 1 and Figure 2. 
Seven subjects were included due to severely disabling migraineous attacks (2 taking 
levetiracetam and 5 taking placebo) and the rest had at least four migraine episodes per 
month. At least one other prophylactic medication had been unsuccessful in 8 
participants taking levetiracetam and 9 taking placebo while 51 individuals had no 
history of previous preventive treatment. Simple analgesics were the most commonly 
used acute migraine treatment in both arms (Supplementary Table 1). For individuals 
who received levetiracetam, doses ranging from 500mg to 3000mg per day were 
administered (Mean±SD: 1120.9±487 mg). 
 
  Primary endpoints 
During the last four weeks of the double-blind phase, the mean migraine frequency 
reduced significantly in the levetiracetam and placebo arms compared to baseline 
(Figure 3). The mean reduction of migraine frequency was statistically greater in 
levetiracetam than in the placebo arm (95%CI: -6.54 to -2.13) (Table 2). The mean 
migraine intensity also reduced significantly in both treatment groups during the last four 
weeks of study period compared to baseline (Figure 3), but the difference was 
significantly greater in those taking levetiracetam (95%CI: -3.04 to -0.38) (Table 2). 
   
Using the ANCOVA sensitivity analysis, the treatment effect defined by the primary 
endpoints remained significant and migraine frequency and intensity of participants 
taking levetiracetam had greater reduction than cases taking placebo (migraine 
frequency [mean difference (95% CI)]: -2.84 (-4.52 to -1.17); migraine intensity [mean 
difference (95% CI)]: -1.68 (-2.95 to -0.41)). 
Exploratory analyses of between-group differences in mean migraine frequency and 
intensity during the first and second four week periods of the double-blind phase also 
showed greater reductions in the levetiracetam arm than in the placebo arm 
(Supplementary Table 2). 
 
  Secondary endpoint 
Levetiracetam was associated with a greater than 50% reduction from baseline 
migraine episodes in 17 (50%) participants at four weeks after initiation of medication; 
19 (56%) after eight weeks, and 21 (62%) after 12 weeks. Six of the participants in the 
levetiracetam arm reported complete elimination of headaches. Conversely, 6 (18%) of 
those in the placebo arm had a greater than 50% reduction from their baseline 
frequency at four weeks after the beginning of double-blind treatment; 8 (24%) after 
eight weeks, and 9 (26%) after 12 weeks. One had a complete cessation of headache 
attacks. Overall, the >50% responder rate was significantly greater in the levetiracetam 
arm than the placebo (p=0.007) (Table 2). 
 
  Safety endpoint 
Adverse events occurred in eight individuals taking levetiracetam. None was significant 
and did not lead to discontinuation of therapy. Overall, irritability (four cases), day-time 
sedation (two cases), and mild tic (two cases) were reported, which all resolved during 
treatment. No side effect was reported in participants receiving placebo. 
 
Safety endpoint 
 Adverse events occurred in eight individuals taking levetiracetam. None was significant 
and did not lead to discontinuation of therapy. Overall, irritability (four cases), day-time 
sedation (two cases), and mild tic (two cases) were reported, which all resolved during 
treatment. No side effect was reported in participants receiving placebo. 
 
Discussion 
 
Summary of results 
  
Levetiracetam and placebo significantly reduced migraine frequency and intensity 
compared to baseline. The reduction in the levetiracetam arm was, however, 
significantly greater than with placebo. Over two thirds of participants in the treatment 
arm reported a reduction of more than 50% from baseline headaches with levetiracetam 
which was significantly greater than with placebo. More participants reported adverse 
events on levetiracetam but safety was similar to placebo. 
 
The annual health-care costs of children diagnosed with migraine are three-fold greater 
than controls (12). These individuals are also prone to developing different neurological 
and mental co-morbidities in the future (13). About 18% of participants (with baseline 
mean migraine frequency of 12  per month) became headache-free after 12 weeks of 
treatment with levetiracetam. Migraine episodes only stopped in one individual on 
placebo.  This difference can be significant from a clinical standpoint. 
 Previous studies 
 
A full search identified six studies (14-19) (Table 3); all suggested that levetiracetam 
could significantly reduce headache frequency. An open-label prospective study (14) 
showed that 90% of people with migraine had a greater than 50% reduction in 
headache frequency while around two-third of our participants in the levetiracetam 
group showed this significant decrease. This discrepancy could possibly be due to 
methodological differences. None of the above-mentioned studies used a control group 
to compare the efficacy of levetiracetam to placebo. In line with this trial, irritability was 
the commonest side-effect in other studies. Overall, irritability, somnolence, dizziness, 
memory defects, weight gain, sleep disturbance and delusion were recorded in studies 
(14-18). These side-effects led to discontinuation of therapy in three cases from two 
studies (14,18). 
 
Levetiracetam was also used as a prophylactic agent for episodic and chronic migraine 
in adults. Prospective double-blind placebo-controlled trials showed that this medication 
produced significant reductions in migraine episodes, as well as attack severity, in adult 
episodic migraine (20,21). One trial showed that individuals in levetiracetam and 
valproate groups had more improvements in headache frequency than those in the 
placebo arm but no significant difference was reported when compared to each other 
(21). Randomized double-blind studies conducted in adults with chronic migraine did not 
show significant efficacy of levetiracetam compared to placebo (22) or valproate (23). 
Side effects including irritability, somnolence, dizziness, hyperactive behavior, 
moodiness, and hostility were also reported in adults (21). 
 
Levetiracetam mechanisms of action 
 
The exact mechanism by which levetiracetam acts is unknown but it probably has 
unique mechanisms of action, binding to the synaptic vesicle protein (SV2A) leading to 
changes in the release of numerous neurotransmitters (24). 
 
To date, levetiracetam and many otherASMs (e.g. topiramate) have been used in 
human and animal studies for prevention of migraine but the underlying mechanisms of 
efficacy are yet unclear. The pathophysiologic link between migraine and epilepsy may 
resolve some of our ambiguities. Increased prevalence of migraine among individuals 
with epilepsy as well as of epilepsy in people with migraine (25) suggests possible 
shared pathophysiology between these conditions. Similarities in clinical features of 
epilepsy and migraine such as presence of premonition, aura, and post-ictal phases 
may suggest elements of pathophysiologic overlay (26) Immune system dysfunctions 
including elevated levels of pro-inflammatory cytokines and autoantibodies are now 
considered in occurrence of epilepsy and migraine (27,28).  
 
Placebo effects 
 
Our results suggest that placebo could also be useful in improving pediatric migraine. A 
recent trial suggested that placebo was more efficacious than topiramate or amitriptyline 
in producing at least 50% reduction in headache-days in children and adolescents (7). 
High placebo-response rates have also been reported in previous headache and pain 
trials (reviewed in 29,30). Placebo effects are neurobiologic changes that may occur 
due to expectations of people with migraine, their caregivers and clinicians (31). 
 
 Limitations and future directions 
 
The small sample size, short follow-up period, and lack of active comparator are major 
limitations of this trial which should be resolved in future studies. As migraine cannot be 
objectively assessed the outcomes of the study were reliant on reports from participants 
or their parents which could lead to information bias. Multiple factors including diet, 
physical activity, and stressors affect migraine occurrence and further studies should 
estimate their impacts on results. Future trials are needed to suggest the most effective 
preventive medications in pediatric migraine. Trying to understand the pathophysiologic 
links between migraine and its co-morbidities may also help find new treatments for 
migraine. Future studies should also identify subgroups that may have the most benefits 
from levetiracetam and other ASMs. 
 
Conclusion 
 
Levetiracetam was more successful than placebo in decreasing migraine episodes and 
their intensity. It was also more effective than placebo in reducing headache frequency 
by 50% in participants in a 12 weeks period.  
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Clinical Implications: 
 Few drugs are available in migraine prophylaxis of pediatric population 
 Levetiracetam may be effective in pediatric migraine prevention 
 Levetiracetam may reduce the number and intensity of migraine episodes; this 
needs replication in larger groups. 
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Figure 1. CONSORT diagram of trial flow 
 
Figure 2. Age distribution of study participants 
 
Figure 3. Mean of migraine frequency per 4 weeks 
 
Figure 4. Mean of migraine intensity per 4 weeks 
 
